UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
|
For the month of October, 2018
|
|
|
|
|
|
|
|
Commission File Number 001-35463
|
|
Taro Pharmaceutical Industries Ltd.
(Translation of registrant’s name into English)
14 Hakitor Street, Haifa Bay 2624761, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.
 |
Taro Pharmaceutical Industries Ltd.
c/o Taro Pharmaceuticals U.S.A., Inc.
Three Skyline Drive
Hawthorne, New York 10532
(NYSE: TARO)
|
|
FOR IMMEDIATE RELEASE
|
|
|
|
|
|
|
|
CONTACTS:
|
|
|
|
Mariano A. Balaguer
|
William J. Coote
|
|
|
VP, CFO
|
AVP, Business Finance, Treasurer and Investor Relations
|
|
| (914) 345-9001 | (914) 345-9001 |
|
| Mariano.Balaguer@taro.com | William.Coote@taro.com |
TARO TO ANNOUNCE SECOND QUARTER RESULTS ON NOVEMBER 5, 2018
Earnings Call to be Conducted Tuesday, November 6 at 8:00 am EST
Hawthorne, NY, October 29, 2018 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2018, on Monday, November 5, 2018.
The Company will conduct an earnings call at 8:00 am EST on Tuesday, November 6, 2018, where senior management will discuss the Company’s performance and answer questions from participants.
The earnings release will be accessible on Taro’s website at www.taro.com.
Earnings Call (8:00 am EST on Tuesday, November 6, 2018)
To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.taro.com. A transcript of this earnings call will also be available on the website.
Summary of events
|
Event
|
Date and time
|
Telephone number/ website
|
|
Earnings release
|
November 5, 2018 (AMC)
|
www.taro.com
|
|
Earnings conference call
|
8:00 am EST
November 6, 2018
|
Participant Toll-Free Dial-In Number: +1 (844) 421-0601
Participant International Dial-In Number: +1 (716) 247-5800
Conference ID: 2871389
Via audio webcast, details of which will be made available on www.taro.com
|
|
Replay of conference call
|
November 6, 2018 to
November 18, 2018
|
+ 1 (855) 859-2056 or +1 (404) 537-3406
Conference ID: 2871389
Via audio webcast playback, details of which will be made available on www.taro.com
|
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 29, 2018
| TARO PHARMACEUTICAL INDUSTRIES LTD. | ||
| By: | /s/ Uday Baldota | |
| Name: Uday Baldota | ||
|
Title: Chief Executive Officer and Director
|
||